Annual EBITDA
-$224.99 M
-$49.59 M-28.28%
December 31, 2023
Summary
- As of February 7, 2025, AXSM annual EBITDA is -$224.99 million, with the most recent change of -$49.59 million (-28.28%) on December 31, 2023.
- During the last 3 years, AXSM annual EBITDA has fallen by -$124.73 million (-124.41%).
- AXSM annual EBITDA is now -12131.76% below its all-time high of -$1.84 million, reached on December 31, 2013.
Performance
AXSM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$60.56 M
+$15.49 M+20.37%
September 30, 2024
Summary
- As of February 7, 2025, AXSM quarterly EBITDA is -$60.56 million, with the most recent change of +$15.49 million (+20.37%) on September 30, 2024.
- Over the past year, AXSM quarterly EBITDA has increased by +$35.97 million (+37.26%).
- AXSM quarterly EBITDA is now -3469.46% below its all-time high of -$1.70 million, reached on September 30, 2014.
Performance
AXSM Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$298.59 M
-$186.00 K-0.06%
September 30, 2024
Summary
- As of February 7, 2025, AXSM TTM EBITDA is -$298.59 million, with the most recent change of -$186.00 thousand (-0.06%) on September 30, 2024.
- Over the past year, AXSM TTM EBITDA has dropped by -$73.60 million (-32.71%).
- AXSM TTM EBITDA is now -17498.51% below its all-time high of -$1.70 million, reached on September 30, 2014.
Performance
AXSM TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
AXSM EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -28.3% | +37.3% | -32.7% |
| 3 y3 years | -124.4% | -82.9% | -151.2% |
| 5 y5 years | -655.3% | -222.2% | -345.2% |
AXSM EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -80.5% | at low | -1185.3% | +37.3% | -141.1% | at low |
| 5 y | 5-year | -235.5% | at low | -1185.3% | +37.3% | -345.2% | at low |
| alltime | all time | <-9999.0% | at low | -3469.5% | +37.3% | <-9999.0% | at low |
Axsome Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$60.56 M(-20.4%) | -$298.59 M(+0.1%) |
| Jun 2024 | - | -$76.05 M(+16.2%) | -$298.41 M(+4.4%) |
| Mar 2024 | - | -$65.44 M(-32.2%) | -$285.72 M(+27.0%) |
| Dec 2023 | -$224.99 M(+28.3%) | -$96.53 M(+59.9%) | -$224.99 M(+20.5%) |
| Sep 2023 | - | -$60.38 M(-4.7%) | -$186.68 M(+11.8%) |
| Jun 2023 | - | -$63.37 M(+1244.8%) | -$167.04 M(+17.7%) |
| Mar 2023 | - | -$4.71 M(-91.9%) | -$141.93 M(-19.0%) |
| Dec 2022 | -$175.40 M(+40.7%) | -$58.23 M(+42.9%) | -$175.19 M(+17.1%) |
| Sep 2022 | - | -$40.73 M(+6.5%) | -$149.57 M(+5.4%) |
| Jun 2022 | - | -$38.26 M(+0.7%) | -$141.95 M(+5.7%) |
| Mar 2022 | - | -$37.98 M(+16.5%) | -$134.26 M(+8.4%) |
| Dec 2021 | -$124.63 M(+24.3%) | -$32.61 M(-1.5%) | -$123.86 M(+4.2%) |
| Sep 2021 | - | -$33.11 M(+8.3%) | -$118.88 M(+9.9%) |
| Jun 2021 | - | -$30.57 M(+10.9%) | -$108.14 M(+13.4%) |
| Mar 2021 | - | -$27.57 M(-0.2%) | -$95.34 M(-4.9%) |
| Dec 2020 | -$100.26 M(+49.5%) | -$27.63 M(+23.5%) | -$100.26 M(+3.3%) |
| Sep 2020 | - | -$22.37 M(+25.9%) | -$97.05 M(+3.8%) |
| Jun 2020 | - | -$17.77 M(-45.3%) | -$93.48 M(+4.9%) |
| Mar 2020 | - | -$32.49 M(+33.0%) | -$89.14 M(+32.9%) |
| Dec 2019 | -$67.07 M | -$24.42 M(+29.9%) | -$67.07 M(+29.0%) |
| Sep 2019 | - | -$18.80 M(+39.9%) | -$51.98 M(+26.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2019 | - | -$13.44 M(+29.1%) | -$41.18 M(+15.3%) |
| Mar 2019 | - | -$10.41 M(+11.5%) | -$35.72 M(+19.9%) |
| Dec 2018 | -$29.79 M(+8.1%) | -$9.34 M(+16.7%) | -$29.79 M(+8.2%) |
| Sep 2018 | - | -$8.00 M(+0.3%) | -$27.53 M(+7.5%) |
| Jun 2018 | - | -$7.98 M(+78.1%) | -$25.61 M(+5.1%) |
| Mar 2018 | - | -$4.48 M(-36.7%) | -$24.38 M(-11.6%) |
| Dec 2017 | -$27.56 M(+1.9%) | -$7.08 M(+16.4%) | -$27.56 M(-0.2%) |
| Sep 2017 | - | -$6.08 M(-9.8%) | -$27.62 M(-3.9%) |
| Jun 2017 | - | -$6.74 M(-12.0%) | -$28.75 M(-0.3%) |
| Mar 2017 | - | -$7.66 M(+7.3%) | -$28.83 M(+6.6%) |
| Dec 2016 | -$27.05 M(+135.8%) | -$7.14 M(-0.8%) | -$27.05 M(+6.7%) |
| Sep 2016 | - | -$7.20 M(+5.5%) | -$25.34 M(+25.7%) |
| Jun 2016 | - | -$6.82 M(+16.0%) | -$20.16 M(+30.7%) |
| Mar 2016 | - | -$5.88 M(+8.3%) | -$15.42 M(+33.5%) |
| Dec 2015 | -$11.47 M(+109.0%) | -$5.43 M(+168.5%) | -$11.55 M(+43.2%) |
| Sep 2015 | - | -$2.02 M(-2.9%) | -$8.07 M(+4.2%) |
| Jun 2015 | - | -$2.08 M(+3.6%) | -$7.74 M(+36.8%) |
| Mar 2015 | - | -$2.01 M(+3.2%) | -$5.66 M(+55.2%) |
| Dec 2014 | -$5.49 M(+198.4%) | -$1.95 M(+14.8%) | -$3.65 M(+114.8%) |
| Sep 2014 | - | -$1.70 M | -$1.70 M |
| Dec 2013 | -$1.84 M | - | - |
FAQ
- What is Axsome Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Axsome Therapeutics?
- What is Axsome Therapeutics annual EBITDA year-on-year change?
- What is Axsome Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Axsome Therapeutics?
- What is Axsome Therapeutics quarterly EBITDA year-on-year change?
- What is Axsome Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Axsome Therapeutics?
- What is Axsome Therapeutics TTM EBITDA year-on-year change?
What is Axsome Therapeutics annual EBITDA?
The current annual EBITDA of AXSM is -$224.99 M
What is the all time high annual EBITDA for Axsome Therapeutics?
Axsome Therapeutics all-time high annual EBITDA is -$1.84 M
What is Axsome Therapeutics annual EBITDA year-on-year change?
Over the past year, AXSM annual EBITDA has changed by -$49.59 M (-28.28%)
What is Axsome Therapeutics quarterly EBITDA?
The current quarterly EBITDA of AXSM is -$60.56 M
What is the all time high quarterly EBITDA for Axsome Therapeutics?
Axsome Therapeutics all-time high quarterly EBITDA is -$1.70 M
What is Axsome Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AXSM quarterly EBITDA has changed by +$35.97 M (+37.26%)
What is Axsome Therapeutics TTM EBITDA?
The current TTM EBITDA of AXSM is -$298.59 M
What is the all time high TTM EBITDA for Axsome Therapeutics?
Axsome Therapeutics all-time high TTM EBITDA is -$1.70 M
What is Axsome Therapeutics TTM EBITDA year-on-year change?
Over the past year, AXSM TTM EBITDA has changed by -$73.60 M (-32.71%)